MedTrace Logo

LMWH to Prevent Preeclampsia and Fetal Growth Restriction

NCT00260520 · Status: TERMINATED · Type: OBSERVATIONAL

Last updated 2006-03-06

No results posted yet for this study

Summary

The objective of this trial will be to determine whether prophylactic low-molecular weight heparin therapy in pregnant women with the heterozygous Factor V Leiden and G20210A prothrombin gene mutations thrombophilia and a history of severe preeclampsia and/or severe fetal growth restriction reduces the risk of the composite outcome of preeclampsia, fetal growth restriction, or both.

Conditions

Interventions

DRUG

Dalteparin

Sponsors & Collaborators

  • University of Florence

    lead OTHER

Principal Investigators

  • Giorgio Mello, MD · Department of Gynecology, Perinatology and Human Reproduction, University of Florence, Italy

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-01-31
Completion
2003-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00260520 on ClinicalTrials.gov